Scarica l'app Stockscreener
53.36
3.05%
-1.68
Precedente Chiudi:
$55.04
Aprire:
$54.1
Volume 24 ore:
451.35K
Relative Volume:
0.68
Capitalizzazione di mercato:
$1.58B
Reddito:
$232.39M
Utile/perdita netta:
$-26.79M
Rapporto P/E:
-49.39
EPS:
-1.0804
Flusso di cassa netto:
$4.41M
1 W Prestazione:
-1.46%
1M Prestazione:
-20.95%
6M Prestazione:
+12.55%
1 anno Prestazione:
+117.35%
Intervallo 1D:
$52.23
$54.52
Intervallo di 1 settimana:
$50.51
$55.90
Portata 52W:
$17.11
$73.30
Anaptysbio Inc Stock (ANAB) Company Profile
Nome
Anaptysbio Inc
Settore
Industria
Telefono
858-362-6295
Indirizzo
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
53.36 | 1.59B | 232.39M | -26.79M | 4.41M | -1.0804 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-22 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-19 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Wells Fargo | Overweight |
| 2024-03-12 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-02-26 | Iniziato | BTIG Research | Buy |
| 2024-02-21 | Iniziato | Stifel | Buy |
| 2024-02-16 | Iniziato | Piper Sandler | Overweight |
| 2023-05-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-13 | Downgrade | Truist | Buy → Hold |
| 2022-09-01 | Iniziato | Raymond James | Outperform |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-03-16 | Aggiornamento | Truist | Hold → Buy |
| 2021-03-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-10-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2019-11-08 | Downgrade | SunTrust | Buy → Hold |
| 2019-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Downgrade | Stifel | Buy → Hold |
| 2018-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-21 | Iniziato | JP Morgan | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-04-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Reiterato | Stifel | Buy |
| 2018-03-06 | Reiterato | Stifel | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2018-01-23 | Reiterato | Credit Suisse | Outperform |
| 2017-11-15 | Iniziato | SunTrust | Buy |
| 2017-11-09 | Iniziato | Jefferies | Buy |
| 2017-10-11 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Anaptysbio Inc Borsa (ANAB) Ultime notizie
Eversept Partners LP Decreases Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc (ANAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AnaptysBio Inc (ANAB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ANAB|AnaptysBio Inc|Price:53.775|Chg%:+0.165 - TradingKey
AnaptysBio Inc (ANAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
First Light Asset Management LLC Decreases Stock Holdings in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc (ANAB) Cash Flow - TradingKey
AnaptysBio Inc (ANAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AnaptysBio Inc (ANAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ANAB|AnaptysBio Inc|Price:53.486|Chg%:-0.124 - TradingKey
ANAB|AnaptysBio Inc|Price:54.150|Chg%:-0.760 - TradingKey
TradingKey - TradingKey
AnaptysBio, Inc. $ANAB Shares Sold by Granahan Investment Management LLC - MarketBeat
AnaptysBio Inc (ANAB) Income Statement - TradingKey
Anaptysbio, Inc Net Worth (2026) - GuruFocus
Affinity Asset Advisors LLC Boosts Position in AnaptysBio, Inc. $ANAB - MarketBeat
Hsbc Holdings PLC Buys New Shares in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc (ANAB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AnaptysBio (NASDAQ:ANAB) Trading Up 5.6%Here's What Happened - MarketBeat
Barclays Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75 - Moomoo
AnaptysBio Declines 2.14% as Shares Test Key Support ZoneVolatility Term Structure - dars.gov.et
AnaptysBio Q1 2026 Earnings: Significant EPS Miss as Pipeline Costs Weigh on ResultsEarnings Call Q&A - dars.gov.et
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), UnitedHealth (UNH) and AnaptysBio (ANAB) - The Globe and Mail
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $95 - Moomoo
AnaptysBio (NASDAQ:ANAB) Shares Down 6.2%Here's Why - MarketBeat
AnaptysBio, Inc.'s Equity Buyback announced on March 24, 2025 has expired with 3,444,079 shares, representing 11.5% for $68.63 million. - marketscreener.com
AnaptysBio (NASDAQ:ANAB) Trading 5.3% HigherShould You Buy? - MarketBeat
Is AnaptysBio (ANAB) Undervalued Following Its Jemperli Royalty Appeal And GSK Trial? - Sahm
AnaptysBio (NASDAQ:ANAB) Shares Gap DownWhat's Next? - MarketBeat
Significant Decline for AnaptysBio (ANAB) as Shares Drop Over 10% - GuruFocus
Barclays Keeps Their Buy Rating on AnaptysBio (ANAB) - The Globe and Mail
AnaptysBio (NASDAQ:ANAB) Shares Down 7%Time to Sell? - MarketBeat
What Makes AnaptysBio (ANAB) an Investment Bet? - Yahoo Finance
Laughing Water Capital Q2 2026 Letter - Seeking Alpha
TD Cowen Remains a Buy on AnaptysBio (ANAB) - The Globe and Mail
Form 144 ANAPTYSBIO For: 13 July By Investing.com - Investing.com Australia
AnaptysBio (NASDAQ: ANAB) insider files to sell 10,694 shares after option exercise - Stock Titan
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75 - Moomoo
AnaptysBio (ANAB) Holds Near Support as Biotech Sentiment Remains CautiousCup and Handle - dars.gov.et
Is AnaptysBio (ANAB) outperforming other medical stocks this year? - MSN
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Should AnaptysBio’s (ANAB) Russell Index Removal Prompt a Rethink of Its Liquidity and Investor Base? - simplywall.st
(ANAB) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Analysts Are Bullish on Top Healthcare Stocks: MindWalk Holdings (HYFT), AnaptysBio (ANAB) - The Globe and Mail
UBS Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $76 - Moomoo
AnaptysBio, Inc. Financial Disclosures & Filings - TradingView
CapForce IBD 50 ETF's AnaptysBio Inc(ANAB) Holding History - GuruFocus
Form 144 ANAPTYSBIO For: 30 June By Investing.com - Investing.com Nigeria
[144] ANAPTYSBIO, INC SEC Filing - Stock Titan
AnaptysBio Is Maintained at Buy by UBS - Moomoo
Is AnaptysBio’s (ANAB) Index Exit and Office Sublease Quietly Reframing Its Strategic Focus? - simplywall.st
Anaptysbio Inc Azioni (ANAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):